Quarterly report · Q2
4671.TEDINET S100S7JG
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥21.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥46.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥24.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥851m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥931m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥629m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥629m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥36.7bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥38.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥38.7bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥10.7bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥12.3bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥26.0bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥26.6bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥24.3bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.2bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥12.6bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥9.2bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.6bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥322m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥249m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥448m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥937m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥56.29 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.34 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥215.29 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥107.5 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.16 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥56.14 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥214.03 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥107.18 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 70.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥270m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥13.0bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥13.0bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥689m |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥385m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥449m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥449m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥46m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥21.3bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥21.3bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥213m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥15.9bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥15.9bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥320m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥293m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥293m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥99m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥24.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥24.2bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥2.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 539
| Item | Context | Value | Unit |
|---|---|---|---|
| Subtotal ope cf | Prior1YTDDuration | 2615000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 1249000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 73000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 55000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -10000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -8000000 | JPY |
| Proceeds from subsidy ope cf | Prior1YTDDuration | 43000000 | JPY |
| Proceeds from subsidy ope cf | CurrentYTDDuration | 1000000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -1271000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | － | JPY |
| Income taxes refund ope cf | Prior1YTDDuration | － | JPY |
| Income taxes refund ope cf | CurrentYTDDuration | 362000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 1451000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 1660000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -350000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -688000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YTDDuration | － | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYTDDuration | 70000000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -43000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -44000000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | -231000000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -1457000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YTDDuration | 372000000 | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYTDDuration | 134000000 | JPY |
| Proceeds from collection of guarantee deposits inv cf | Prior1YTDDuration | 16000000 | JPY |
| Proceeds from collection of guarantee deposits inv cf | CurrentYTDDuration | 149000000 | JPY |
| Proceeds from cancellation of insurance funds inv cf | Prior1YTDDuration | － | JPY |
| Proceeds from cancellation of insurance funds inv cf | CurrentYTDDuration | 62000000 | JPY |
| Payments for guarantee deposits inv cf | Prior1YTDDuration | -4000000 | JPY |
| Payments for guarantee deposits inv cf | CurrentYTDDuration | － | JPY |
| Other net inv cf | Prior1YTDDuration | -9000000 | JPY |
| Other net inv cf | CurrentYTDDuration | -77000000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -249000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -1851000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | -100000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | 500000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -383000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -2340000000 | JPY |
| Repayments of finance lease obligations fin cf | Prior1YTDDuration | -133000000 | JPY |
| Repayments of finance lease obligations fin cf | CurrentYTDDuration | -146000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -378000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -761000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | － | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -489000000 | JPY |
| Proceeds from sales of treasury stock fin cf | Prior1YTDDuration | 57000000 | JPY |
| Proceeds from sales of treasury stock fin cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -937000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -3237000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 0 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 0 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |